AH: Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer

Ladenburg, Germany, 24 November 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the Supervisory Board has revoked the appointment of Professor Andreas Pahl as member of the Executive Management Board and Chief Executive Officer, and has instead appointed Dr Dongzhou Jeffery Liu as Chairman of the Executive Management Board and new Chief Executive Officer, with immediate effect.  

Dr Liu has stepped down from his position as a member of the Supervisory Board of Heidelberg Pharma, with effect as of 23 December 2025. His permanent appointment as Chairman of the Executive Management Board and Chief Executive Officer will become effective as of 24 December 2025. For the transition period from today until 23 December 2025 he will be seconded as a deputy member to the Executive Management Board pursuant to section 105 (2) of the German Stock Corporation Act (Aktiengesetz).

Dr Liu is Chief Scientific Officer (CSO) and President of Huadong Global Development at Huadong Medicine in Hangzhou, China. Prior to that he held various leading positions in the pharma industry in the US, including GlaxoSmithKline, Wyeth (now Pfizer) and Forest Labs (now Abbvie). His more than 25 years of industry experience include clinical and preclinical research & development of medicinal products, including ADC products.